SalariusLogo2ColorNoTag.jpg
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
08. Februar 2022 08:00 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
SalariusLogo2ColorNoTag.jpg
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
13. Januar 2022 07:00 ET | Salarius Pharmaceuticals, Inc.
Transformative acquisition significantly expands Salarius’ oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area...
fior-markets-logo.jpg
Global Hematological Cancers Therapeutics Market Is Expected to Reach USD 82.40 billion by 2028 : Fior Markets
11. Februar 2021 19:00 ET | Fior Markets
Newark, NJ, Feb. 11, 2021 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global haematological cancer therapeutics market is expected to grow from USD 37.88 billion in 2020 and...
TELO-new LOGO.jpg
Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer’s Disease
11. November 2020 12:26 ET | Telo Genomics Corp.
TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has received final approval and grant of three of its pending...
NotableLabs-Logo-07 (2).png
Notable to Host July 23 Webinar with Stanford Cancer Institute and MDS Foundation: Emerging Treatment Approaches for Higher Risk Myelodysplastic Syndromes
13. Juli 2020 11:00 ET | Notable Labs
FOSTER CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...
precision oncology in hematological cancers
Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies
23. Juni 2020 11:00 ET | Notable Labs
FOSTER CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...